Toxic mushrooms may hold secrets to tackling deadly diseases as researchers have discovered that the fungi could help in the production of medicines capable of curing disease without the patient suffering any side effects.
The researchers discovered in mushrooms an enzyme called POPB that create the mushroom's molecules that harbour missile-like proficiency in attacking and annihilating a single vulnerable target in the human liver.
These findings could lead to single-minded medicines with zero side effects, said co-lead author Jonathan Walton, professor of plant biology at the Michigan State University in the US.
The team revealed how the enzyme contributes to the manufacture of chemical compounds known as cyclic peptides, a favourite molecule that pharmaceutical companies use to create new drugs.
"Mushrooms are prolific chemical factories, yet only a few of their peptides are poisonous," he added.
"These toxins survive the high temperatures of cooking and the acids of digestion, and yet they are readily absorbed by the bloodstream and go directly to their intended target. These are the exact qualities needed for an effective medicine," Walton said.
The enzyme POPB convert the toxins from their initial linear shape into cyclic peptides, fortress-like molecular circles comprising eight amino acids.
Harnessing the distinct properties of POPB will allow scientist to create billions of variant molecules, which can be tested against many different medical targets such as pathogenic bacteria and cancer, the researchers said.
For the study, the scientists worked with the mushroom species Amanita.
The study appeared in the journal Chemistry and Biology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
